Latest Ratings for MCHP Date Firm Action From To Mar 2022 UBS Maintains Buy Feb 2022 Rosenblatt Maintains Buy Jan 2022 UBS Upgrades Neutral Buy View More Analyst Ratings for MCHP View the Latest Analyst Ratings read more
Latest Ratings for DTE Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 B of A Securities Upgrades Underperform Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for DTE View the Latest Analyst Ratings read more
Latest Ratings for MS Date Firm Action From To Jan 2022 Odeon Capital Downgrades Buy Hold Jan 2022 UBS Maintains Buy Jan 2022 Barclays Maintains Overweight View More Analyst Ratings for MS View the Latest Analyst Ratings read more
Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy. read more
Latest Ratings for CNP Date Firm Action From To Feb 2022 Citigroup Maintains Neutral Feb 2022 UBS Upgrades Neutral Buy Jan 2022 Goldman Sachs Downgrades Buy Neutral View More Analyst Ratings for CNP View the Latest Analyst Ratings read more
Economic data shows mixed U.S. market close, construction spending up, ISM manufacturing PMI surpasses expectations. Most S&P 500 sectors decline, Dow falls. Asian markets up. read more
